{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kallus S"],"funding":["Austrian Science Fund FWF","Mahlke geb. Obermann-Stiftung of the University of Vienna"],"pagination":["2632-2643"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7611408"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(8)"],"pubmed_abstract":["Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated the FGFR inhibitors ponatinib, PD173074, and nintedanib into polylactic acid nanoparticles and liposomes to enable increased tumor accumulation/specificity and reduce side effects. Different methods of drug loading were tested and the resulting formulations compared regarding average size distribution as well as encapsulation efficiency. Appropriate encapsulation levels were achieved for liposomal preparations only. Nanoencapsulation resulted in significantly decelerated uptake kinetics in vitro with clearly decreased short-term (up to 72 h) cytotoxicity at higher concentrations. Ho"],"journal":["Nanomedicine : nanotechnology, biology, and medicine"],"pubmed_title":["Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index."],"pmcid":["PMC7611408"],"funding_grant_id":["P30105","P 28853","FA526009","P 30105","P28853"],"pubmed_authors":["Laemmerer A","Kowol CR","Senkiv J","Berger W","Keppler BK","Englinger B","Kallus S","Heffeter P"],"additional_accession":[]},"is_claimable":false,"name":"Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index.","description":"Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated the FGFR inhibitors ponatinib, PD173074, and nintedanib into polylactic acid nanoparticles and liposomes to enable increased tumor accumulation/specificity and reduce side effects. Different methods of drug loading were tested and the resulting formulations compared regarding average size distribution as well as encapsulation efficiency. Appropriate encapsulation levels were achieved for liposomal preparations only. Nanoencapsulation resulted in significantly decelerated uptake kinetics in vitro with clearly decreased short-term (up to 72 h) cytotoxicity at higher concentrations. Ho","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Nov","modification":"2025-04-18T22:15:26.498Z","creation":"2022-02-11T00:28:32.14Z"},"accession":"S-EPMC7611408","cross_references":{"pubmed":["30121385"],"doi":["10.1016/j.nano.2018.08.001"]}}